Propranolol Alleviates Cardiac Injury After Acute Catecholamine Infusion Through p38-MAPK Pathways

Tzu-Hao Liu1, Rebecca Jen-Ling Hsieh2, Hsin-Hung Chen2

  • 1Department of Pediatrics, Zuoying Armed Forces General Hospital, Kaohsiung, Taiwan.

Insights

Severe hypercatecholaminergic conditions cause heart failure. Propranolol (1 mg/kg) bolus treatment significantly reduced cardiac damage and fibrosis in rats by modulating the p-38 MAPK pathway.

Area of Science:

  • Cardiology
  • Pharmacology
  • Molecular Biology

Background:

  • Hypercatecholaminergic conditions can lead to severe heart failure and cardiac fibrosis.
  • Previous research on beta-blockade in catecholaminergic states has limitations in realistic models.
  • The precise benefits of beta-blockade in hyper-adrenergic states require further investigation.

Purpose of the Study:

  • To investigate the acute cardiac changes in a rat model of catecholamine-induced heart failure.
  • To evaluate the efficacy of propranolol treatment in mitigating these cardiac changes.
  • To elucidate the molecular pathways involved in catecholamine-induced cardiac damage and the effects of propranolol.

Main Methods:

  • Male Sprague-Dawley rats underwent a 6-hour infusion of epinephrine and norepinephrine.
  • One group received an additional propranolol (1 mg/kg) bolus at hour 1.
  • Cardiac tissues were analyzed after 6 hours using immunohistochemistry.

Main Results:

  • Catecholamine infusion alone increased reactive oxidative species and profibrosis proteins, decreasing phosphorylated p-38.
  • Propranolol treatment normalized phosphorylated p-38 levels and downregulated apoptotic and profibrotic pathways.
  • Key profibrotic mediators including MMP-9, α-SMA, and FGF23 were implicated.

Conclusions:

  • Catecholamine-induced heart failure involves the p-38 MAPK pathway, profibrosis, and apoptosis.
  • A single propranolol bolus (1 mg/kg) effectively attenuated acute catecholamine-induced cardiac damage.
  • Propranolol mitigates catecholamine excess by targeting the p-38 MAPK pathway, profibrosis, and apoptosis.

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
685
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
571
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
635
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
416